J&J, Basilea To File Ceftobiprole For Hospital-Acquired Pneumonia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Basilea Pharmaceuticals plans to file the antibiotic ceftobiprole "as soon as possible" for the treatment of hospital-acquired pneumonia and community-acquired pneumonia requiring hospitalizations following positive Phase III results, CEO Anthony Man stated during an Oct. 9 conference call announcing the results